Table 1. Main characteristics of all studies included in the meta-analysis.
| Author,year | Race(country) | No. of patients(M/F) | Stage | Histology distribution | Antibody sorce(Dilution) | Cutoff value | Distribution of reduced E-cadherin (%) | Outcome |
| Kase,2000 [14] | Asian(Japan) | 331(209/122) | I–IV | AD227,SQ104 | Transduction(1∶2500) | 0.7 | 42 | OS,CP |
| Kimura,2000 [15] | Asian(Japan) | 135(90/45) | I–IV | AD101,SQ25,LCC5,ADS4 | DAKO(NR) | 0.8 | 64.4 | OS,CP |
| Lee,2000 [16] | Asian(Taiwan) | 207(142/65) | I–III | AD98,SQ74,BAC35 | Takara(NR) | 0.4 | 41 | OS,CP |
| Hirata,2001 [17] | Asian(Japan) | 249(171/78) | I–IIIA | AD148,SQ90,LCC8 | Takara(NR) | 0.1 | 47 | OS,CP |
| Deeb,2004 [18] | Caucasian(USA) | 118(63/55) | I–IIIA | AD81,SQ37 | Dako(1∶50) | 0.1 | 45 | OS,CP |
| Huang,2005 [19] | Asian(Japan) | 173(116/57) | I–III | AD101,SQ58,LCC14 | Vector(1∶100) | 0.5 | 57 | OS,CP |
| Tamura,2005 [20] | Asian(Japan) | 131(97/34) | I–IIIA | AD81,SQ50 | Takara(1∶200) | 0.75 | 54 | OS,CP |
| Al-Saad,2008 [21] | Caucasian(Norway) | 335(253/82) | I–IIIA | AD95,SQ191,LCC31,BAC18 | Rocklin(NR) | Score = 2 | 40 | OS |
| Cho,2008 [22] | Asian(Korea) | 55(31/24) | I | AD55 | Zymed(NR) | 0.25 | 13 | DFS |
| Zhu,2009 [23] | Asian(China) | 148(114/34) | IB | AD42,SQ58,LCC2,BAC27,other19 | Fuzhou maxim(NR) | ROC | 12.8 | OS |
| Ono,2010 [24] | Asian(Japan) | 107(71/36) | I | AD74,other33 | BD(1∶200) | 0.7 | 17 | DFS |
| Yamashita,2010 [25] | Asian(Japan) | 117(77/40) | I | AD78,SQ31,LCC6,other2 | BD(1∶200) | 0.7 | 40 | OS,CP |
| Lin,2010 [26] | Asian(China) | 185(115/70) | I | SQ63,non-SQ132 | Takara(1∶400) | 0.5 | 51 | OS |
| Sterlacci,2010 [27] | Caucasian(Austria) | 405(292/113) | I–IV | AD207,SQ126,LCC56,other16 | DAKO(NR) | 0.25 | 51 | OS |
| Ucvet,2011 [28] | Caucasian(Turkey) | 117(111/6) | I–IV | AD47,SQ62,LCC7,other1 | BioGenex(1∶10) | 0.5 | 75 | OS |
| Yu,2011 [29] | Asian(China) | 44(22/22) | I–IV | AD44 | Santa Cruz(1∶200) | 0.75 | 57 | OS,CP |
| Yu,2011 [29] | Asian(China) | 57(42/15) | I–IV | SQ57 | Santa Cruz(1∶200) | 0.75 | 60 | OS,CP |
| Richardson,2012 [30] | Caucasian(USA) | 38(NR) | I–IV | NR | Danvers(1∶50) | 0.1 | 68 | PFS |
| Wu,2012 [31] | Asian(China) | 50(38/12) | I–III | AD14,SQ36 | Labvision(NR) | Score = 1 | 52 | OS,CP |
| Feng,2012 [32] | Asian(China) | 103(71/32) | I–IV | AD46,SQ55 | Invitrogen(1∶200) | 0.1 | 66 | OS |
| Kim,2013 [33] | Asian(Korea) | 193(90/103) | I–III | AD193 | BD(1∶200) | Score = 100 | 18 | OS,CP |
| Zhang X,2013 [34] | Asian(China) | 118(76/42) | I–IIIA | AD35,SQ74,other9 | BD(1∶400) | 0.66 | 48 | OS |
| Zhang H,2013 [35] | Asian(China) | 204(173/31) | I–IIIA | SQ | Invitrogen(1∶200) | Score = 4 | 49.5 | OS,CP |
| Zhao C,2013 [36] | Asian(China) | 119(93/26) | I–IV | AD61,SQ58 | Santa Cruz(1∶100) | 0.1 | 53.9 | OS |
| Lim,2000 [37] | Asian(Korea) | 175(162/13) | I–IV | AD20.6,SQ79.4 | DAKO(NR) | 0.5 | 46.8 | CP |
| Pagaki,2010 [38] | Caucasian(Greece) | 70 | I–IV | AD23.9,SQ67.1 | Menarini(NR) | 0.1 | 55.7 | CP |
| Jin,2012 [39] | Asian(China) | 46(28/18) | I–III | AD43.5,SQ37.0 | Maixin(1∶50) | 0.25 | 60.9 | CP |
| Shi,2013 [40] | Asian(China) | 95(56/39) | I–IV | AD95 | Zymed(1∶200) | Score = 4 | 56.8 | CP |
| Zhao J,2013 [41] | Asian(China) | 50(39/11) | I–IV | AD25,SQ19,LCC6 | Zymed(NR) | 0.6 | 44 | CP |
M: male; F: female; AD: adenocarcinoma; SQ: squamous cell carcinoma; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; CP: Clinicopathological parameters; NR: not reported.